FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904047548> ?p ?o ?g. }

• W2904047548 endingPage "758" @default.
• W2904047548 startingPage "752" @default.
• W2904047548 abstract "PurposeTo examine the relationship between serum oxidized low-density lipoprotein (ox-LDL) cholesterol and the incidence of age-related macular degeneration (AMD) over a 25-year period in a sample of persons from the population-based Beaver Dam Eye Study (BDES).DesignObservational prospective cohort study.ParticipantsA total of 4972 people from the BDES (aged 43–84 years and living in Beaver Dam, Wisconsin in 1988) seen during at least 1 of 6 examination phases at approximately 5-year intervals between 1988 and 2016.MethodsA 50% random sample of participants (N = 2468) was selected for ox-LDL measurements. Stored frozen specimens from every examination phase were processed using an enzyme-linked immunosorbent assay from a single batch. All available intervals were included for a person, resulting in 6586 person-visits.Main Outcome MeasuresAge-related macular degeneration was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was defined using a 5-step severity scale. The severity of the worse eye at each examination was used for analyses. A multi-state Markov (MSM) model was fit to simultaneously assess the ox-LDL relationship to all AMD transitions, including incidence of any AMD, incidence of late AMD, and worsening and improvement of AMD over the 25 years of the study.ResultsThe mean (standard deviation) level of ox-LDL was 75.3 (23.1) U/L at the baseline examination. When adjusting for age, sex, ARMS2 and CFH risk alleles, and examination phase, the ox-LDL at the beginning of a period was not statistically significantly associated with the incidence of any AMD (hazard ratio per 10 U/L ox-LDL was 1.03, 95% confidence interval 0.98,1.09). Furthermore, ox-LDL was not associated with worsening anywhere along the AMD severity scale, nor with incidence of late AMD. The lack of relationships of ox-LDL to the incidence of any AMD or worsening of AMD remained after adjustment for history of statin use, smoking status, body mass index, and history of cardiovascular disease (data not shown).ConclusionsOur findings do not provide evidence for statistically significant relationships between ox-LDL and AMD disease development or worsening of AMD. To examine the relationship between serum oxidized low-density lipoprotein (ox-LDL) cholesterol and the incidence of age-related macular degeneration (AMD) over a 25-year period in a sample of persons from the population-based Beaver Dam Eye Study (BDES). Observational prospective cohort study. A total of 4972 people from the BDES (aged 43–84 years and living in Beaver Dam, Wisconsin in 1988) seen during at least 1 of 6 examination phases at approximately 5-year intervals between 1988 and 2016. A 50% random sample of participants (N = 2468) was selected for ox-LDL measurements. Stored frozen specimens from every examination phase were processed using an enzyme-linked immunosorbent assay from a single batch. All available intervals were included for a person, resulting in 6586 person-visits. Age-related macular degeneration was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was defined using a 5-step severity scale. The severity of the worse eye at each examination was used for analyses. A multi-state Markov (MSM) model was fit to simultaneously assess the ox-LDL relationship to all AMD transitions, including incidence of any AMD, incidence of late AMD, and worsening and improvement of AMD over the 25 years of the study. The mean (standard deviation) level of ox-LDL was 75.3 (23.1) U/L at the baseline examination. When adjusting for age, sex, ARMS2 and CFH risk alleles, and examination phase, the ox-LDL at the beginning of a period was not statistically significantly associated with the incidence of any AMD (hazard ratio per 10 U/L ox-LDL was 1.03, 95% confidence interval 0.98,1.09). Furthermore, ox-LDL was not associated with worsening anywhere along the AMD severity scale, nor with incidence of late AMD. The lack of relationships of ox-LDL to the incidence of any AMD or worsening of AMD remained after adjustment for history of statin use, smoking status, body mass index, and history of cardiovascular disease (data not shown). Our findings do not provide evidence for statistically significant relationships between ox-LDL and AMD disease development or worsening of AMD." @default.
• W2904047548 created "2018-12-22" @default.
• W2904047548 creator A5005374772 @default.
• W2904047548 creator A5024539691 @default.
• W2904047548 creator A5026764667 @default.
• W2904047548 creator A5045425466 @default.
• W2904047548 creator A5061631272 @default.
• W2904047548 creator A5073734270 @default.
• W2904047548 date "2019-05-01" @default.
• W2904047548 modified "2023-09-26" @default.
• W2904047548 title "Oxidized Low-density Lipoprotein and the Incidence of Age-related Macular Degeneration" @default.
• W2904047548 cites W1494726320 @default.
• W2904047548 cites W1789824814 @default.
• W2904047548 cites W185914786 @default.
• W2904047548 cites W1966368391 @default.
• W2904047548 cites W1977060705 @default.
• W2904047548 cites W1979228140 @default.
• W2904047548 cites W1988245456 @default.
• W2904047548 cites W1992390260 @default.
• W2904047548 cites W1997480136 @default.
• W2904047548 cites W2017136158 @default.
• W2904047548 cites W2021122140 @default.
• W2904047548 cites W2024963329 @default.
• W2904047548 cites W2025215568 @default.
• W2904047548 cites W2030628584 @default.
• W2904047548 cites W2030956577 @default.
• W2904047548 cites W2036806484 @default.
• W2904047548 cites W2039982938 @default.
• W2904047548 cites W2042969150 @default.
• W2904047548 cites W2044488811 @default.
• W2904047548 cites W2054286986 @default.
• W2904047548 cites W2070847516 @default.
• W2904047548 cites W2076300837 @default.
• W2904047548 cites W2092460143 @default.
• W2904047548 cites W2094026248 @default.
• W2904047548 cites W2104443849 @default.
• W2904047548 cites W2106772107 @default.
• W2904047548 cites W2136128927 @default.
• W2904047548 cites W2138902509 @default.
• W2904047548 cites W2140181275 @default.
• W2904047548 cites W2144839999 @default.
• W2904047548 cites W2155965977 @default.
• W2904047548 cites W2161143583 @default.
• W2904047548 cites W2162103288 @default.
• W2904047548 cites W2167449978 @default.
• W2904047548 cites W2266045994 @default.
• W2904047548 cites W2513843538 @default.
• W2904047548 cites W2607031541 @default.
• W2904047548 cites W2738996050 @default.
• W2904047548 cites W4205543610 @default.
• W2904047548 cites W4210631414 @default.
• W2904047548 cites W2330300383 @default.
• W2904047548 doi "https://doi.org/10.1016/j.ophtha.2018.12.026" @default.
• W2904047548 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6475598" @default.
• W2904047548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30572074" @default.
• W2904047548 hasPublicationYear "2019" @default.
• W2904047548 type Work @default.
• W2904047548 sameAs 2904047548 @default.
• W2904047548 citedByCount "14" @default.
• W2904047548 countsByYear W29040475482020 @default.
• W2904047548 countsByYear W29040475482021 @default.
• W2904047548 countsByYear W29040475482022 @default.
• W2904047548 countsByYear W29040475482023 @default.
• W2904047548 crossrefType "journal-article" @default.
• W2904047548 hasAuthorship W2904047548A5005374772 @default.
• W2904047548 hasAuthorship W2904047548A5024539691 @default.
• W2904047548 hasAuthorship W2904047548A5026764667 @default.
• W2904047548 hasAuthorship W2904047548A5045425466 @default.
• W2904047548 hasAuthorship W2904047548A5061631272 @default.
• W2904047548 hasAuthorship W2904047548A5073734270 @default.
• W2904047548 hasBestOaLocation W29040475481 @default.
• W2904047548 hasConcept C118487528 @default.
• W2904047548 hasConcept C120665830 @default.
• W2904047548 hasConcept C121332964 @default.
• W2904047548 hasConcept C126322002 @default.
• W2904047548 hasConcept C134018914 @default.
• W2904047548 hasConcept C141071460 @default.
• W2904047548 hasConcept C188816634 @default.
• W2904047548 hasConcept C2776403814 @default.
• W2904047548 hasConcept C2777155141 @default.
• W2904047548 hasConcept C2778257484 @default.
• W2904047548 hasConcept C2778313320 @default.
• W2904047548 hasConcept C2781116099 @default.
• W2904047548 hasConcept C2908647359 @default.
• W2904047548 hasConcept C555293320 @default.
• W2904047548 hasConcept C61511704 @default.
• W2904047548 hasConcept C71924100 @default.
• W2904047548 hasConcept C72563966 @default.
• W2904047548 hasConcept C99454951 @default.
• W2904047548 hasConceptScore W2904047548C118487528 @default.
• W2904047548 hasConceptScore W2904047548C120665830 @default.
• W2904047548 hasConceptScore W2904047548C121332964 @default.
• W2904047548 hasConceptScore W2904047548C126322002 @default.
• W2904047548 hasConceptScore W2904047548C134018914 @default.
• W2904047548 hasConceptScore W2904047548C141071460 @default.
• W2904047548 hasConceptScore W2904047548C188816634 @default.
• W2904047548 hasConceptScore W2904047548C2776403814 @default.
• W2904047548 hasConceptScore W2904047548C2777155141 @default.

• next